Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms that have made announcements.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading – for better or worse – and then I do my best to make sense of who’s moving where and why it might be happening.
Anyway… here’s what’s been happening since the doors were opened this morning: The ASX got off to a decent start this morning, opening around +0.7% higher after an unusual session on Wall Street overnight, with local InfoTech stocks struggling for traction while the rest of the market climbed.
WINNERS
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Security Description Last % Change Volume MktCap MSG MCS Services 0.002 100.0 111,513 $198,100 EXT Excite Technology 0.009 28.6 2,118,815 $10,179,692 88E 88 Energy 0.0025 25.0 2,582,612 $57,785,344 ALR Altair Minerals 0.005 25.0 1,742,701 $17,186,310 CTO Citigold 0.005 25.0 1,000,000 $12,000,000 PUA Peak Minerals 0.005 25.0 100,000 $4,165,506 KLI Killi Resources 0.105 20.7 6,452,703 $10,459,466 RNX Renegade Exploration 0.012 20.0 585,324 $12,800,534 USL Unico Silver 0.22 18.9 956,592 $55,324,544 SKS SKS Tech Group 1.35 17.9 372,723 $128,010,261 3DP Pointerra 0.055 17.0 2,881,785 $37,838,609 IMM Immutep 0.345 16.9 6,004,920 $428,520,626
SKS Technologies (ASX:SKS) was up on news that it has been awarded a $90+ million data centre project with Built, for an “international hyperscale data centre” in Melbourne, to be completed by August 2025. SKS has also revised its revenue guidance for FY25 to ‘more than $200 million’.
Pointerra (ASX:3DP) was up, after delivering a corporate / investor webinar this morning. That’s about as much as I know about it at this stage.
And Immutep (ASX:IMM) was rising after it announced positive results from Cohort B of the TACTI-003 Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.
LAGGARDS
Stocks highlighted in red have made market-moving announcements (click headings to sort).
Code Company Price % Volume Market Cap TAS Tasman Resources Ltd 0.003 -40.0 28,125 $3,563,346 HLX Helix Resources 0.002 -20.0 5,370,000 $8,160,484 MEL Metgasco Ltd 0.004 -20.0 65,445 $7,237,934 SMM Somerset Minerals 0.004 -20.0 64,000 $5,154,994 VRC Volt Resources Ltd 0.004 -20.0 252,588 $20,793,391 GBZ GBM Rsources Ltd 0.009 -18.2 1,607,736 $12,723,578 TM1 Terra Metals Limited 0.087 -17.1 13,222,620 $38,259,763 RNE Renu Energy Ltd 0.005 -16.7 800,000 $4,356,804 OVT Ovanti Limited 0.006 -14.3 17,501 $8,680,738 VML Vital Metals Limited 0.003 -14.3 232,574 $20,632,734
The post Top 10 at 11: A positive drug trial and investor webinars are making news today appeared first on Stockhead.
